Relative <i>APOBEC3A</i> and MeV <i>M</i> mRNA quantification upon MeV infections in cells stably expressing DNase I. by Pierre Khalfi (7868252)

Analysis of mitochondrial morphology in Notch mutants and Notch signaling in Opa1 depleted type II NB lineages. by Dnyanesh Dubal (12085942)

Subjects:

Analysis of change in mature INPs, GMCs and neurons in the type II NB lineage on depletion of mitochondrial morphology proteins. by Dnyanesh Dubal (12085942)

Subjects:

Downregulation of Opa1 and Marf does affect type II NB numbers but affect differentiated cells in lineage. by Dnyanesh Dubal (12085942)

Subjects:

TMEM182 decreases OSCC cell motility. by En-Wei Hsing (154990)

Fig 2 - by Takumi Tanaka (1977604)

Maximum concentrations (ng/L) of 88 pharmaceuticals detected at least once (in order of decreasing number of detections across all regions and samples) in water samples from wadeab... by Paul M. Bradley (523469)

Summary of the effects of HBc linker mutants on different steps of viral replication. by Ji Xi (5244308)

“…N/A, not applicable due to the lack of detection of RC DNA; -/+, very weak signal detected; -, below the limit of detection; unstab, unstable NC; stab, stable NC as WT; *, CCC DNA decreased during infection. +, CCC DNA generated but no detectable core RC DNA, so CCC DNA/RC DNA normalization was impossible. …”

Data_Sheet_1_Microclimatic Warming Leads to a Decrease in Species and Growth Form Diversity: Insights From a Tropical Alpine Grassland.PDF by Sisimac A. Duchicela (11503918)

“…The increase of tussocks and decrease in diversity of species and growth forms due to prolonged modifications in microclimatic temperature might be a step toward shrub-dominated ecosystems. …”

Proliferation defects in Opa1 depleted type II NB lineages are suppressed by overexpression of Drp1^SD. by Dnyanesh Dubal (12085942)

Subjects:

Evaluation of glucose consumption and lactate production in culture medium of HL-1 cells exposed to LG, NG, HG and IHG during 12 and 72h. by Patrick Mordel (17020879)

Source data for Fig 1. by Rahsan Erdem (11726357)

Source data for Fig 2. by Rahsan Erdem (11726357)

Source data for Fig 3. by Rahsan Erdem (11726357)

Demographics and baseline characteristics of the safety population. by Rahsan Erdem (11726357)

Grading of stool consistency and diarrhea severity. by Rahsan Erdem (11726357)

Secondary efficacy endpoints for the modified intent-to-treat population. by Rahsan Erdem (11726357)

Source data for S1 and S2 Figs. by Rahsan Erdem (11726357)

Consolidated Standards for Reporting of Trials flow diagram. by Rahsan Erdem (11726357)

Diarrheal disease severity by treatment group for the modified intent-to-treat population. by Rahsan Erdem (11726357)